RiceBran Technologies (RIBT) 10-Q 10 Nov 16 2016 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2016	Nov. 04, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	RiceBran Technologies
Entity Central Index Key	1,063,537
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		10,800,686
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q3
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2016

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Condensed Consolidated Statements of Operations (Unaudited) [Abstract]
Revenues	$ 8,824	$ 8,917	$ 29,420	$ 29,982
Cost of goods sold	6,918	6,860	23,293	24,634
Gross profit	1,906	2,057	6,127	5,348
Operating expenses:
Selling, general and administrative	3,737	2,977	11,454	9,817
Depreciation and amortization	309	426	965	1,360
Goodwill impairment	0	0	3,024	0
Total operating expenses	4,046	3,403	15,443	11,177
Loss from operations	(2,140)	(1,346)	(9,316)	(5,829)
Other income (expense):
Interest income	84	23	94	91
Interest expense - accreted on debt	(94)	(57)	(497)	(395)
Interest expense - other	(652)	(704)	(2,081)	(2,039)
Change in fair value of derivative warrant liabilities	1,166	654	314	1,211
Gain on resolution of Irgovel purchase litigation	0	0	1,598	0
Foreign currency exchange, net	(27)	(93)	111	(281)
Loss on extinguishment of debt	0	0	0	(1,904)
Other income	132	2	133	167
Other expense	(19)	(55)	(160)	(214)
Total other income (expense)	590	(230)	(488)	(3,364)
Loss before income taxes	(1,550)	(1,576)	(9,804)	(9,193)
Income tax benefit	0	6	0	19
Net loss	(1,550)	(1,570)	(9,804)	(9,174)
Net loss attributable to noncontrolling interest in Nutra SA	470	1,046	2,416	2,122
Net loss attributable to RiceBran Technologies shareholders	(1,080)	(524)	(7,388)	(7,052)
Dividend on preferred stock-beneficial conversion feature	0	0	(551)	0
Net loss attributable to RiceBran Technologies common shareholders	$ (1,080)	$ (524)	$ (7,939)	$ (7,052)
Loss per share attributable to RiceBran Technologies common shareholders
Basic (in dollars per share)	$ (0.11)	$ (0.06)	$ (0.86)	$ (0.77)
Diluted (in dollars per share)	$ (0.11)	$ (0.06)	$ (0.86)	$ (0.77)
Weighted average number of shares outstanding
Basic (in shares)	9,397,255	9,222,150	9,281,942	9,181,607
Diluted (in shares)	9,397,255	9,222,150	9,281,942	9,181,607

Condensed Consolidated Stateme3

Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) [Abstract]
Net loss	$ (1,550)	$ (1,570)	$ (9,804)	$ (9,174)
Other comprehensive income (loss) - foreign currency translation, net of tax	(165)	(1,501)	694	(2,731)
Comprehensive loss, net of tax	(1,715)	(3,071)	(9,110)	(11,905)
Comprehensive loss attributable to noncontrolling interest, net of tax	330	1,528	1,998	3,022
Total comprehensive loss attributable to RiceBran Technologies shareholders	$ (1,385)	$ (1,543)	$ (7,112)	$ (8,883)

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 2,199	$ 1,070
Restricted cash	0	1,921
Accounts receivable, net of allowance for doubtful accounts of $604 and $512, respectively (variable interest entity restricted $222 and $1,003, respectively)	2,666	2,169
Inventories	3,875	3,857
Operating taxes recoverable	4	809
Deposits and other current assets	749	895
Total current assets	9,493	10,721
Property and equipment, net (variable interest entity restricted $2,449 and $2,102, respectively)	19,347	18,328
Goodwill	790	3,258
Intangible assets, net	476	1,225
Operating taxes recoverable	998	0
Other long-term assets	122	103
Total assets	31,226	33,635
Current liabilities:
Accounts payable	3,889	2,514
Accrued salary, wages and benefits	3,672	2,325
Accrued expenses	4,387	4,789
Current maturities of long-term debt (variable interest entity nonrecourse $6,849 and $2,750, respectively)	11,982	5,050
Total current liabilities	23,930	14,678
Long-term debt, less current portion (variable interest entity nonrecourse $0 and $3,553, respectively)	5,063	10,908
Derivative warrant liabilities	2,838	678
Deferred tax liability	34	34
Total liabilities	31,865	26,298
Commitments and contingencies
Temporary equity
Preferred stock, Series F, convertible, 20,000,000 shares authorized, 3,000 convertible shares issued and outstanding at September 30, 2016	551	0
Redeemable noncontrolling interest in Nutra SA	0	69
Total temporary equity	551	69
(Deficit) Equity attributable to RiceBran Technologies shareholders:
Common stock, no par value, 25,000,000 shares authorized, 10,800,686 and 9,537,415 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively	263,831	262,895
Accumulated deficit	(258,677)	(250,738)
Accumulated deficit attributable to noncontrolling interest in Nutra SA	(1,929)	0
Accumulated other comprehensive loss	(4,415)	(4,889)
Total (deficit) equity attributable to RiceBran Technologies shareholders	(1,190)	7,268
Total liabilities, temporary equity and (deficit) equity	$ 31,226	$ 33,635

Condensed Consolidated Balance5

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Current assets:
Accounts receivable, allowance for doubtful accounts	$ 604	$ 512
Current liabilities:
Current portion of long-term debt (nonrecourse)	11,982	5,050
Long-term liabilities:
Long-term debt, less current portion (nonrecourse)	$ 5,063	$ 10,908
Equity attributable to RiceBran Technologies shareholders:
Common stock, par value (in dollars per share)	$ 0	$ 0
Common stock, shares authorized (in shares)	25,000,000	25,000,000
Common stock, shares issued (in shares)	10,800,686	9,537,415
Common stock, shares outstanding (in shares)	10,800,686	9,537,415
Variable Interest Entity [Member]
Current assets:
Accounts receivable, variable interest entity restricted	$ 222	$ 1,003
Variable interest entity restricted portion of property and equipment, net	2,449	2,102
Current liabilities:
Current portion of long-term debt (nonrecourse)	6,849	2,750
Long-term liabilities:
Long-term debt, less current portion (nonrecourse)	$ 0	$ 3,553
Series F Convertible Preferred Stock [Member]
Temporary equity
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000
Convertible preferred stock, shares issued (in shares)	3,000
Convertible preferred stock, shares outstanding (in shares)	3,000

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Cash flow from operating activities:
Net loss	$ (9,804)	$ (9,174)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	2,256	3,196
Stock and share-based compensation	841	627
Change in fair value of derivative warrant and conversion liabilities	(314)	(1,211)
Goodwill impairment	3,024	0
Gain on resolution of Irgovel purchase litigation	(1,598)	0
Loss on extinguishment of debt	0	1,904
Deferred tax benefit	0	(19)
Interest accreted	497	395
Other	98	213
Changes in operating assets and liabilities:
Accounts receivable	(377)	(550)
Inventories	146	(726)
Accounts payable and accrued expenses	2,953	1,318
Other	206	(486)
Net cash used in operating activities	(2,072)	(4,513)
Cash flows from investing activities:
Change in restricted cash	1,921	0
Purchases of property and equipment	(460)	(991)
Net cash provided by (used in) investing activities	1,461	(991)
Cash flows from financing activities:
Payments of debt	(28,773)	(14,789)
Proceeds from issuance of debt, net of issuance costs	27,650	0
Proceeds from issuance of debt and warrants, net of issuance costs	300	17,979
Proceeds from issuance of preferred stock and warrants, net of issuance costs	2,554	0
Proceeds from sale of membership interests in Nutra, SA	200	0
Payment of payroll taxes on stock-based compensation through shares withheld	(9)	0
Net cash provided by financing activities	1,922	3,190
Effect of exchange rate changes on cash and cash equivalents	(182)	227
Net change in cash and cash equivalents	1,129	(2,087)
Cash and cash equivalents, beginning of period	1,070	3,610
Cash and cash equivalents, end of period	2,199	1,523
Supplemental disclosures:
Cash paid for interest	1,319	1,306
Cash paid for income taxes	$ 20	$ 0

BASIS OF PRESENTATION

BASIS OF PRESENTATION	9 Months Ended
	Sep. 30, 2016
BASIS OF PRESENTATION [Abstract]
BASIS OF PRESENTATION	NOTE 1. BASIS OF PRESENTATION In the opinion of management, the accompanying unaudited condensed consolidated financial statements (interim financial statements) of RiceBran Technologies and subsidiaries were prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and the rules and regulations of the Securities and Exchange Commission (SEC) for reporting on Form 10-Q; therefore, as permitted under these rules, certain footnotes and other financial information included in audited financial statements were condensed or omitted. The interim financial statements contain all adjustments necessary to present fairly the interim results of operations, financial position and cash flows for the periods presented. These interim financial statements should be read in conjunction with the consolidated audited financial statements and notes thereto in our Annual Report on Form 10-K for the year ended December 31, 2015. The report of our independent registered public accounting firm that accompanies the audited consolidated financial statements for the year ended December 31, 2015, included in that Annual Report on Form 10-K, contains a going concern explanatory paragraph in which our independent registered public accounting firm expressed substantial doubt about our ability to continue as a going concern. The results reported in these interim financial statements are not necessarily indicative of the results to be expected for the full fiscal year, or any other future period, and have been prepared assuming we will continue as a going concern based on the realization of assets and the satisfaction of liabilities in the normal course of business. Certain reclassifications have been made to amounts reported for the prior year to achieve consistent presentation with the current year. These reclassifications had no effect on the Company’s results of operations for any of the periods presented. Recent Accounting Guidance Recent accounting guidance not yet adopted In August 2014, the Financial Accounting Standards Board (FASB) issued guidance which requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of the date the financial statements are issued and provides guidance on determining when and how to disclose going concern uncertainties in the financial statements. Certain disclosures will be required if conditions give rise to substantial doubt about an entity’s ability to continue as a going concern The guidance applies to all entities and is effective for annual periods ending after December 15, 2016, and interim periods thereafter, with early adoption permitted. We will adopt this standard in the fourth quarter of 2016, and we do not expect the adoption to have a material effect on our results of operations. In May 2014, the FASB issued guidance on revenue from contracts with customers to clarify the principles for recognizing revenue and develop a common revenue standard for GAAP and International Financial Reporting Standards. Under the new guidance, an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services, applying the following steps: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. The guidance is effective for our annual and interim periods beginning in 2018. Early adoption is permitted. We have not yet determined the impact that the new guidance will have on our results of operations and financial position and have not yet determined if we will early adopt the standard. In February 2016, the FASB issued guidance which changes the accounting for leases. Under prior GAAP, the recognition, measurement and presentation of expenses and cash flows arising from a lease for us as a lessee depend primarily on the lease’s classification as a finance or operating lease. For both types of leases, lessees will recognize a right-of-use asset and a lease liability. For capital or finance leases, lessees will recognize amortization of the right-of-use asset separately from interest expense on the lease liability. The guidance is effective for our annual and interim periods beginning in 2019 and must be adopted on a modified retrospective approach. Early adoption is allowed. We have not yet determined the impact that the new guidance will have on our results of operations, financial position and cash flows and have not yet determined if we will early adopt the standard. In March 2016, the FASB issued new guidance that changes the accounting for certain aspects of share-based payments to employees. The new guidance requires excess tax benefits and tax deficiencies to be recorded in the income statement when the awards vest or are settled. In addition, cash flows related to excess tax benefits will no longer be separately classified as a financing activity apart from other income tax cash flows. The guidance also allows us to repurchase more of an employee’s shares for tax withholding purposes without triggering liability accounting, clarifies that all cash payments made on an employee’s behalf for withheld shares should be presented as a financing activity on our cash flows statement, and provides an accounting policy election to account for forfeitures as they occur. The guidance is effective for our annual and interim periods beginning in 2017 with early adoption permitted. We plan to adopt the standard in the first quarter of 2017 and change our accounting policy to recognize forfeitures as they occur. This change will not have a material effect on our results of operations as we currently do not apply an estimated forfeiture rate to restricted stock awards to our officers and directors. Additionally, most of our outstanding stock option awards vest on a monthly basis over the vesting period (generally three or four years). As these awards do not have performance conditions, the expense is recognized each month on a straight-line basis and excludes the effect of the estimated forfeiture rate as there is no risk of expensing awards that would be subsequently forfeited prior to vesting. In June 2016, the FASB issued a new credit loss standard that replaces the incurred loss impairment methodology in current GAAP. The new impairment model requires immediate recognition of estimated credit losses expected to occur for most financial assets and certain other instruments. It is effective for annual reporting periods beginning after December 15, 2019 and interim periods within those annual periods. Early adoption for fiscal years beginning after December 15, 2018 is permitted. Entities will apply the standard’s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first effective reporting period. We have not yet determined the impact that the new guidance will have on our results of operations, financial position and cash flows and have not yet determined if we will early adopt the standard Recently adopted accounting guidance In February 2015, the FASB issued guidance which makes targeted amendments to current consolidation guidance. Among other things, the standard changes the manner in which we would assess one of the characteristics of variable interest entities (VIEs) and introduces a separate analysis specific to limited partnerships and similar entities (such as Nutra SA, LLC) for assessing if the equity holders at risk lack decision making authority. Limited partnerships and similar entities will be a VIE unless the limited partners hold substantive kick-out rights or participating rights. A right to liquidate an entity is akin to a kick-out right. Guidance for limited partnerships under the voting model has been eliminated. A limited partner and similar partners with a controlling financial interest obtained through substantive kick-out rights would consolidate a limited partnership or similar entity. Upon adoption in the first quarter of 2016, there was no impact on our financial position or results of operations. Specifically, under the new guidance, we continue to be the primary beneficiary of Nutra SA, LLC.

LIQUIDITY, GOING CONCERN AND MA

LIQUIDITY, GOING CONCERN AND MANAGEMENT'S PLAN	9 Months Ended
	Sep. 30, 2016
LIQUIDITY, GOING CONCERN AND MANAGEMENT'S PLAN [Abstract]
LIQUIDITY, GOING CONCERN AND MANAGEMENT'S PLAN	NOTE 2. LIQUIDITY, GOING CONCERN AND MANAGEMENT’S PLAN We continued to experience losses and negative cash flows from operations which raises substantial doubt about our ability to continue as a going concern. We believe that we will be able to obtain additional funds to operate our business, should it be necessary; however, there can be no assurances that our efforts will prove successful. The accompanying interim financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern. The Brazil segment consists of the consolidated operations of Nutra SA, LLC (Nutra SA), whose only operating subsidiary is Industria Riograndens De Oleos Vegetais Ltda. ( In May 2015, the USA segment entered into an $8 million senior secured credit facility agreement with a lender (the Lender) consisting of a $3.5 million revolving loan, not to exceed a borrowing base, as defined in the agreement, and an initial $2.5 million term loan, which term loan may be increased at the Lender’s discretion by up to $2.0 million within 2 years. As a result of the credit facility transaction, the notes for a majority of the subordinated note holders representing approximately 97% of the principal due were amended, resulting in a $1.9 million loss on extinguishment. In February 2016, we issued and sold preferred stock and warrants that netted proceeds of $2.6 million. Funds received under the facility with the Lender and from the February offering are being used for working capital and capital expenditure needs in both of our operating segments. In March 2016, the restricted cash previously held in a $1.9 million escrow account associated with the purchase of Irgovel (see Note 9) was released to us pursuant to a court order. We repaid $1.0 million of the term loan with the Lender upon receipt of funds from the escrow account. In addition, we repaid a $0.3 million short-term note from a related party (see Note 12). Beginning in the second quarter of 2016 and through the third quarter of 2016, the Brazil segment has experienced severe cash shortages resulting in an increase in accounts payable (principally to raw bran suppliers) and accrued payroll related tax obligations as we delayed non-essential payments. The nonpayment of working capital liabilities has resulted in suppliers refusing to ship raw bran and other materials necessary to maintain steady operation of the plant. In addition to the working capital issues, the funds necessary to meet scheduled debt payments no longer exist without additional equity funding. As a result, the Brazil segment ceased making all bank debt payments in the second and third quarters of 2016. Discussions have ensued with the related banks with regard to renegotiation of existing debt agreements. However, there is no assurance these discussions will be successful. In October 2016, our minority partner contributed $1.2 million to Irgovel. Additionally, Irgovel’s management has negotiated various raw bran supply agreements that will allow Irgovel to obtain rice bran on a consistent basis with set pricing. We continue to closely monitor Irgovel’s operations and related funding requirements.

BUSINESS

BUSINESS	9 Months Ended
	Sep. 30, 2016
BUSINESS [Abstract]
BUSINESS	NOTE 3. BUSINESS We are a human food ingredient, nutritional supplement and animal nutrition company focused on value-added processing and marketing of healthy, natural and nutrient dense products derived from raw rice bran, an underutilized by-product of the rice milling industry. Using our bio-refining business model, we apply our proprietary and patented technologies and intellectual properties to convert raw rice bran into numerous high value products including: stabilized rice bran (SRB); rice bran oil (RBO); defatted rice bran (DRB); RiBalance, a complete rice bran nutritional package derived from further processing of SRB; RiSolubles, a highly nutritious, carbohydrate and lipid rich fraction of RiBalance; RiFiber, a fiber rich insoluble derivative of RiBalance; ProRyza, rice bran protein-based products, and a variety of other valuable derivatives extracted from these core products. Our target markets are natural food, functional food, nutraceutical supplement and animal nutrition manufacturers, wholesalers and retailers, both domestically and internationally. We have two reportable operating segments: (i) USA segment, which manufactures and distributes SRB (for human food ingredient and animal nutrition customers) in various granulations along with Stage II products and derivatives and (ii) Brazil segment, which extracts crude RBO and DRB from rice bran, which are then further processed into fully refined rice bran oil for sale internationally and in Brazil, compounded animal nutrition products for horses, cows, swine, sheep and poultry and a number of valuable human food and animal nutrition products derivatives and co-products. Stage II refers to the proprietary processes run at our Dillon, Montana facility and includes products produced at that facility using our patented processes. In addition we incur corporate and other expenses not directly attributable to reportable operating segments, which include costs related to our corporate staff, general and administrative expenses including public company expenses, intellectual property, professional fees and other expenses. No corporate allocations, including interest, are made to the reportable operating segments. The combined operations of our USA and Brazil segments encompass our bio-refining approach to processing raw rice bran into various high quality, value-added constituents and finished products. Over the past decade, we have developed and optimized our proprietary bio-refining processes to support the production of healthy, natural, hypoallergenic, gluten free and non-genetically modified ingredients and supplements for use in human meats, baked goods, cereals, coatings, health foods, nutritional supplements, nutraceuticals and high-end animal nutrition and health products. The USA segment produces SRB inside two supplier rice mills in California and our facility in Mermentau, Louisiana. The USA segment also includes our Dillon, Montana Stage II facility which produces our Stage II products: RiBalance, RiSolubles, RiFiber, ProRyza and a variety of other valuable derivatives extracted from these core products. The manufacturing facilities included in our USA segment have proprietary processing equipment and process patented technology for the stabilization and further processing of rice bran into finished products. The Brazil segment consists of the consolidated operations of Nutra SA, whose only operating subsidiary is Irgovel, located in Pelotas, Brazil. Irgovel manufactures RBO and DRB products for both the human ingredient and animal nutrition markets in Brazil and internationally. In refining RBO to an edible grade, several co-products are obtained. One such product is distilled fatty acids, a valuable raw material for the detergent industry. DRB is either compounded with a number of other ingredients to produce complex animal nutrition products which are packaged and sold under Irgovel brands in the Brazilian market, sold as a raw material for further processing into human food ingredients or sold in bulk into the animal nutrition markets in Brazil and neighboring countries.

LOSS PER SHARE (EPS)

LOSS PER SHARE (EPS)	9 Months Ended
	Sep. 30, 2016
LOSS PER SHARE (EPS) [Abstract]
LOSS PER SHARE (EPS)	NOTE 4. LOSS PER SHARE (EPS) Basic EPS is calculated under the two-class method under which all earnings (distributed and undistributed) are allocated to each class of common stock and participating securities based on their respective rights to receive dividends. Our Series F Convertible Preferred Stock (the Series F Preferred Stock) is considered a participating security as the security holders may participate in undistributed earnings with holders of common shares. The holders of the Series F Preferred Stock are not obligated to share in net losses of the Company. Diluted EPS is computed by dividing the net income attributable to RiceBran Technologies shareholders by the weighted average number of shares outstanding during the period increased by the number of additional shares that would have been outstanding if the impact of assumed exercises and conversions is dilutive. The dilutive effect of outstanding options, warrants and nonvested shares that vest solely on the basis of a service condition is calculated using the treasury stock method. The dilutive effect of the Series F Preferred Stock is calculated using the if-converted method. Below are reconciliations of the numerators and denominators in the EPS computations for the three and nine months ended September 30, 2016 and 2015. Three Months Ended Nine Months Ended 2016 2015 2016 2015 NUMERATOR (in thousands): Basic and diluted - net loss attributable to RiceBran Technologies shareholders $ (1,080 ) $ (524 ) $ (7,388 ) $ (7,052 ) Dividend on preferred stock--beneficial conversion feature - - (551 ) - Basic and diluted - net loss attributable to RiceBran Technologies common shareholders $ (1,080 ) $ (524 ) $ (7,939 ) $ (7,052 ) DENOMINATOR: Basic EPS - weighted average number of common shares outstanding 9,397,255 9,222,150 9,281,942 9,181,607 Effect of dilutive securities outstanding - - - - Diluted EPS - weighted average number of shares outstanding 9,397,255 9,222,150 9,281,942 9,181,607 Number of shares of common stock which could be purchased with weighted average outstanding securities not included in diluted EPS because effect would be antidilutive: Stock options 340,037 341,315 350,203 288,751 Warrants 10,842,006 7,093,628 10,132,045 6,808,513 Nonvested stock 1,114,747 300,779 1,038,019 212,156 Convertible preferred stock 2,000,000 - 1,611,722 - The impact of potentially dilutive securities outstanding at September 30, 2016 and 2015, was not included in the calculation of diluted EPS for the three and nine months ended September 30, 2016 for the periods presented

GOODWILL

GOODWILL	9 Months Ended
	Sep. 30, 2016
GOODWILL [Abstract]
GOODWILL	NOTE 5. GOODWILL The following table reflects goodwill allocated to each reporting segment at September 30, 2016 2015 (in thousands) USA Segment Brazil Segment Total Goodwill Balance, December 31, 2015 $ 790 $ 2,468 $ 3,258 Goodwill impairment - (3,024 ) (3,024 ) Effect of change in exchange rates - 556 556 Balance, September 30, 2016 $ 790 $ - $ 790 Several economic factors occurred during the second quarter of 2016, specifically related to our Brazil segment, including a decline in raw bran availability and continuing operating losses resulting in a lack of working capital. Due to the lack of working capital, the Brazil segment ceased making all bank debt payments in the second quarter of 2016. $3.0 million

REDEEMABLE NONCONTROLLING INTER

REDEEMABLE NONCONTROLLING INTEREST IN NUTRA SA	9 Months Ended
	Sep. 30, 2016
REDEEMABLE NONCONTROLLING INTEREST IN NUTRA SA [Abstract]
REDEEMABLE NONCONTROLLING INTEREST IN NUTRA SA	NOTE 6. REDEEMABLE NONCONTROLLING INTEREST IN NUTRA SA We hold a variable interest which relates to our equity interest in Nutra SA (see Note 2). Our variable interest in Nutra SA is our Brazil segment. We are the primary beneficiary of Nutra SA, and as such, Nutra SA’s assets, liabilities and results of operations are included in our condensed consolidated financial statements. The other equity holders’ (Investors) interests are reflected in net loss attributable to noncontrolling interest in Nutra SA in the condensed consolidated statements of operations and redeemable noncontrolling interest in Nutra SA in the condensed consolidated balance sheets. Due to the goodwill impairment charge recorded in the second quarter of 2016 combined with continuing operating losses, the carrying amount of the redeemable noncontrolling interest reflects a deficit balance beginning in the second quarter of 2016. This deficit balance is reflected in the total (deficit) equity attributable to RiceBran Technologies shareholders section of our condensed consolidated balance sheet at September 30, 2016. Prior to June 30, 2016, the redeemable noncontrolling interest was reflected in the total temporary equity section of our condensed consolidated balance sheet. A summary of the carrying amounts of Nutra SA balances included in our condensed consolidated balance sheets follows (in thousands). September 30, December 31, 2016 2015 Cash and cash equivalents $ 67 $ 104 Other current assets (restricted $222 and $1,003) 919 2,760 Property and equipment, net (restricted $2,449 and $2,102) 11,138 9,502 Goodwill and intangibles, net - 2,468 Other noncurrent assets 1,061 43 Total assets $ 13,185 $ 14,877 Current liabilities $ 7,867 $ 4,647 Current portion of long-term debt (nonrecourse) 6,849 2,750 Long-term debt, less current portion (nonrecourse) - 3,553 Total liabilities $ 14,716 $ 10,950 Nutra SA’s debt is secured by its accounts receivable and property. The non-Brazilian entities within the consolidated ownership group do not guarantee any of Nutra SA’s debt. Cash provided by operations in our Brazil segment is generally unavailable for distribution to our Corporate and USA segments pursuant to the terms of the limited liability company agreement of Nutra SA (LLC Agreement). During the first nine months of 2016, we invested an additional $1.1 million in Nutra SA. Upon receipt of the escrow funds by us on March 24, 2016 (see Note 9), Nutra SA redeemed a certain number of units held by us equal to $1.7 million, which resulted in a slight decrease in our membership interest in Nutra SA. Our membership interest subsequently changed due to additional investments by us and by our minority partner. In October 2016, our minority partner contributed $1.2 million to Nutra SA. A summary of changes in redeemable noncontrolling interest in Nutra SA for the three and nine months ended September 30, 2016 and 2015 (in thousands) follows. Three Months Ended Nine Months Ended 2016 2015 2016 2015 Redeemable noncontrolling interest in Nutra SA, beginning of period $ (1,599 ) $ 862 $ 69 $ 2,643 Investors' interest in net loss of Nutra SA (470 ) (1,046 ) (2,416 ) (2,122 ) Investors' interest in accumulated other comprehensive loss of Nutra SA (60 ) (482 ) 218 (900 ) Investors' purchase of additional units 200 - 200 - Accumulated Yield classified as other current liability - 861 - 574 Redeemable noncontrolling interest in Nutra SA, end of period $ (1,929 ) $ 195 $ (1,929 ) $ 195 Investors' average interest in Nutra SA during the period 32.5 % 32.1 % 32.2 % 33.2 % Investors' interest in Nutra SA at the end of the period 32.7 % 32.1 % 32.7 % 32.1 % The Investors have drag along rights which allow the Investors to force a sale of Nutra SA assets after January 1, 2018. The right terminates upon the occurrence of certain events (a $50 million Nutra SA initial public offering or a change of control, as defined in the LLC Agreement). We may elect to exercise a right of first refusal to purchase the Investors’ interest instead of proceeding to a sale. We have assessed the likelihood of the Investors exercising these rights as less than probable at September 30, 2016. We will continue to evaluate the probability of the Investors exercising their drag along rights each reporting period. We will begin to accrete the redeemable noncontrolling interest up to fair value if and when it is probable the Investors will exercise these rights. The Investors may elect, until January 1, 2018, to exchange units in Nutra SA for our common stock (the Exchange Right). The appraised fair value of the Investors’ interest in Nutra SA and the market price of our stock would be used to determine the amount of ownership interest the Investors would receive. The shares issued to the Investors may not exceed 49% of our outstanding common stock after such issuance; however, if this limitation applies, we would be required to issue to the Investors a warrant to purchase a number of shares of our common stock that, when combined with the shares of common stock issued to the Investors, would equal 49% of our fully diluted shares outstanding after such issuance. Under the LLC Agreement, the business of Nutra SA is to be conducted by the manager, currently our CEO, subject to the oversight of the management committee. The management committee is comprised of three of our representatives and two Investor representatives. Upon an event of default or a qualifying event, we will no longer control the management committee and the management committee will include three Investor representatives and two of our representatives. In addition, following an event of default or a qualifying event, a majority of the members of the management committee may replace the manager of Nutra SA. As of September 30, 2016, there have been no unwaived events of default. Events of default, as defined in the Membership Interest Purchase Agreement (MIPA) and the October 2013 amendment of investment agreements, are failure of Irgovel to meet minimum annual processing targets or failure to achieve EBITDA on a local currency basis of at least R$4.0 million annually. As of September 30, 2016, there have been no qualifying events. The LLC Agreement defines a qualifying event as the bankruptcy of RiceBran Technologies or Nutra SA. In evaluating whether we are the primary beneficiary of Nutra SA, we considered the matters which could be put to a vote of the members. Until there is an event of default or a qualifying event, the Investors’ rights and abilities, individually or in the aggregate, do not allow them to substantively participate in the operations of Nutra SA. The Investors do not currently have the ability to dissolve Nutra SA or otherwise force the sale of all its assets. However, the Investors do have drag along rights in the future. We will continue to evaluate whether we are the primary beneficiary of Nutra SA each reporting period.

DEBT

DEBT	9 Months Ended
	Sep. 30, 2016
DEBT [Abstract]
DEBT	NOTE 7. DEBT The following table summarizes current and long-term portions of debt (in thousands): September 30, December 31, 2016 2015 Corporate segment: Senior revolving loan $ 2,866 $ 1,617 Senior term loan, net 946 1,407 Subordinated notes, net, maturing in May 2018, principal $6.3 million 6,310 6,310 Subordinated notes, net, paid in July 2016, principal $0 - 205 Other 74 116 10,196 9,655 Brazil segment: Capital expansion loans 2,417 2,067 Working capital lines of credit 584 828 Advances on customer export orders 1,113 1,310 Special tax programs 2,703 2,064 Other 32 34 6,849 6,303 Total debt 17,045 15,958 Current portion 11,982 5,050 Long-term portion $ 5,063 $ 10,908 In January 2016, we entered into a note payable with a director in the principal amount of $0.3 million and issued the director a warrant to acquire 25,000 shares of common stock (exercise price of $5.25, exercisable immediately and expiring in January 2021). e repaid the note and accumulated interest in full in March 2016. In February 2016, we entered into an agreement with the Lender which modified the financial covenants to require that (a) from February 1, 2016 to July 15, 2016, we maintain cash on hand, including availability under our revolving loan with the Lender, of not less than $1.5 million, provided that at least $0.8 million of such amount must be in the form of cash on hand, and (b) we maintain an average monthly adjusted EBITDA, as defined by the agreement, calculated over each consecutive three-month period beginning on January 1, February 1, March 1, April 1 and May 1, 2016, of not less than $0.1 million. The Lender also waived, for the first three quarters of 2016, any non-compliance with the financial covenants in the May 2015 agreement. We may not be able to comply with the original May 2015 covenants without further modifications from the Lender. Therefore, as of September 30, 2016, we have recorded the term loan, net of related debt issuance costs, as a current portion of long-term debt. As of September 30, 2016, we are in compliance with the financial covenants associated with our debt agreements, as modified and discussed above. In March 2016, we repaid $1.0 million of the senior term loan principal outstanding, which as of December 31, 2015, had been scheduled to be repaid in 2018, as required under the February agreement with the Lender described above. In the first quarter of 2016, we expensed $0.2 million of debt issuance costs to interest expense as a result of that repayment. We also paid a $0.1 million amendment fee in the first quarter of 2016, which is included in interest expense in our condensed consolidated statement of operations. We also paid an approximately $0.2 million amendment fee in the third quarter of 2016, which was added to the outstanding loan balance. Beginning in the second quarter of 2016, the Brazil segment did not have sufficient working capital to make their scheduled debt payments, and, as a result, the Brazil segment ceased making all bank debt payments in the second and third quarters. Therefore, we have recorded all Brazil segment debt as current, regardless of maturity date. Discussions have ensued with the related banks with regard to renegotiation of existing debt agreements. However, there is no assurance these discussions will be successful.

EQUITY, SHARE-BASED COMPENSATIO

EQUITY, SHARE-BASED COMPENSATION AND WARRANTS	9 Months Ended
	Sep. 30, 2016
EQUITY, SHARE-BASED COMPENSATION AND WARRANTS [Abstract]
EQUITY, SHARE-BASED COMPENSATION AND WARRANTS	NOTE 8. EQUITY, SHARE-BASED COMPENSATION AND WARRANTS In February 2016, our board of directors authorized the issuance of 3,000 shares of Series F Preferred Stock. The Series F Preferred Stock is non-voting and may be converted into a total of 2,000,000 shares of our common stock at the holder’s election at any time, subject to certain beneficial ownership limitations, at a ratio of 1 preferred share for 666.66666 shares of common stock. The Series F Preferred Stock is only entitled to receive dividends if we declare dividends, in which case the dividend will be paid (i) first an amount equal to $0.01 per share of preferred stock and (ii) then to and in the same form as dividends paid on shares of our common stock. Otherwise, the Series F Preferred Stock has no liquidation or other preferences over our common stock. The number of common shares and warrants issuable if the Investors elect the Exchange Right is variable and indeterminate. For accounting purposes, we are not able to conclude that we have sufficient authorized and unissued shares to settle all contracts subject to the FASB’s derivative guidance. Our adopted sequencing approach is based on earliest issuance date (the Share Sequencing), therefore we are required to record certain warrants issued after the right was granted to the Investors in June 2015 at fair value, as derivative warrant liabilities. For the same reason, the A summary of equity activity for the nine months ended September 30, 2016, (in thousands, except share data) follows. Common Stock Accumulated Accumulated Deficit Attributable to Noncontrolling Interest in Accumulated Other Comprehensive Total (Deficit) Shares Amount Deficit Nutra SA Loss Equity Balance, December 31, 2015 9,537,415 $ 262,895 $ (250,738 ) $ - $ (4,889 ) $ 7,268 Share-based compensation, employees and directors - 619 - - - 619 Issuance of preferred stock and warrants - (447 ) - - - (447 ) Dividend on preferred stock--beneficial conversion feature - 551 (551 ) - - - Issuance of common stock to supplier 950,000 - - - - - Other 313,271 213 - - - 213 Accumulated deficit attributable to noncontrolling interest in Nutra SA - - - (1,929 ) - (1,929 ) Foreign currency translation - - - - 474 474 Net loss - - (7,388 ) - - (7,388 ) Balance, September 30, 2016 10,800,686 $ 263,831 $ (258,677 ) $ (1,929 ) $ (4,415 ) $ (1,190 ) In February 2016, we issued 950,000 shares of common stock to a supplier. In September 2016, we issued shares of common stock to directors at a grant date fair value of $1.46 per share. We issued 174,825 shares which vest on the earlier of June 30, 2017 or one day before the date of the next annual shareholder meeting. A summary of warrant activity for the nine months ended September 30, 2016, follows. Equity Warrants Liability Warrants Shares Underlying Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Shares Underlying Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Outstanding, December 31, 2015 6,367,139 $ 5.78 3.4 726,489 $ 5.24 2.9 Issued - NA 2,685,000 2.03 4.5 Impact of anti-dilution clauses - NA 1,063,379 1.50 1.3 Exercised - NA - NA Forfeited, expired or cancelled - NA - NA Outstanding, September 30, 2016 6,367,139 $ 5.78 2.7 4,474,868 $ 1.82 3.6 Exercisable, September 30, 2016 6,367,139 $ 5.78 2.7 4,474,868 $ 1.82 3.6 In January 2016, we entered into a note payable with a director in the principal amount of $0.3 million and issued the director a warrant to acquire 25,000 share of common stock (exercise price of $5.25, exercisable immediately and expiring in January 2021). e repaid the note and accumulated interest in full in March 2016. In February 2016, in conjunction with the sale of the Series F Preferred Stock, we also In June 2016, we entered into an amendment agreement with our Lender to extend the prior modification of the loan agreement. In connection with this amendment, we repriced a previously issued warrant held by the Lender from $5.25 per share to $1.85 per share. Both prior to and subsequent to these modifications , with changes in fair value recorded in the condensed consolidated statements of operations.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2016
COMMITMENTS AND CONTINGENCIES [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 9. COMMITMENTS AND CONTINGENCIES In addition to the matters discussed below, from time to time we are involved in litigation incidental to the conduct of our business. We record accruals for contingencies when it is probable that a liability will be incurred and the amount of loss can be reasonably estimated. Legal costs are expensed as incurred and are included in professional fees. While the outcome of lawsuits and other proceedings against us cannot be predicted with certainty, in the opinion of management, individually or in the aggregate, no such lawsuits are expected to have a material effect on our financial position, results of operations or cash flows. Irgovel Purchase On August 28, 2008, former Irgovel stockholder David Resyng filed an indemnification suit against Irgovel, Osmar Brito and the remaining former Irgovel stockholders (Sellers), requesting: (i) the freezing of the escrow account maintained in connection with the transfer of Irgovel’s corporate control to us and the presentation of all documentation related to the transaction, and (ii) damages in the amount of the difference between (a) the sum received by David Resyng in connection with the judicial settlement agreement executed in the action for the partial dissolution of the limited liability company filed by David Resyng against Irgovel and the Sellers and (b) the amount received by the Sellers in connection with the sale of Irgovel’s corporate control to us, in addition to moral damages as determined in the court’s discretion. The amount of damage claimed by Mr. Resyng is approximately $3.0 million. We believe that the filing of the above lawsuit is a fundamental default of the obligations undertaken by the Sellers under the quotas purchase agreement for the transfer of Irgovel’s corporate control, executed by and among the Sellers and us on January 31, 2008 (Purchase Agreement). Consequently, we believe that the responsibility for any indemnity, costs and expenses incurred or that may come to be incurred by Irgovel and/or us in connection with the above lawsuit is the sole responsibility of the Sellers. On February 6, 2009, the Sellers filed a collection lawsuit against us seeking payment of the second installment of the purchase price under the Purchase Agreement, which the Sellers assert is approximately $1.0 million. We have withheld payment of the second installment pending resolution of the Resyng lawsuit noted above. RiceBran Technologies, the parent company, has not been served with any formal notices in regard to this matter. To date, only Irgovel has received formal legal notice. In addition, the Purchase Agreement requires that all disputes between us and the Sellers be adjudicated through arbitration. In 2015, a final unappealable arbitration award was granted in our favor. We are considering collection actions against the Sellers for amounts awarded in excess of the escrow funds described below and have a contingent gain in an amount that is not currently determinable. As part of the Purchase Agreement, $2.0 million was deposited into an escrow account to cover contingencies with the net remaining funds payable to the Sellers upon resolution of all contingencies. As of December 31, 2015, the balance in the escrow account was $1.9 million and was included in restricted cash in our condensed consolidated balance sheet. With regard to the request for freezing the escrow funds noted above, the Brazilian court ordered Irgovel not to access those funds under the premise that the Sellers may have a right to those funds as originally contemplated in the Purchase Agreement. A fine of R$10,000 per day for violating that order was established by the court. From the escrow release date of March 24, 2016 through today, no fine has been imposed. We believe that with the final judgment in our favor, the Sellers no longer have any possible legal claim on the escrow funds and, thus, the court will remove the freeze. We are working with counsel in Brazil to effectuate that outcome. We believe that there are no significant remaining contingencies. We recognized a gain of $1.6 million in the first quarter of 2016, equal to the difference between the $1.9 million escrow liability and the $0.3 million of resolved pre-acquisition contingencies that had either been paid or specifically identified and accrued. Irgovel - Events of Default As further described in Note 6, Irgovel is required to meet minimum annual processing targets or to achieve EBITDA in local currency of at least R$4.0 million annually. If not achieved, this would result in an event of default. It is possible that an event of default may be triggered in the future and a waiver of non-compliance may not be obtained from the Investors. Employment Contracts and Severance Payments We have employment contracts with certain officers and key management that include provisions for potential severance payments in the event of without-cause terminations or terminations under certain circumstances after a change in control. In addition, vesting of outstanding nonvested equity grants would accelerate following a change in control. See Note 14 for severance information related to our former chief executive officer.

SEGMENT INFORMATION

SEGMENT INFORMATION	9 Months Ended
	Sep. 30, 2016
SEGMENT INFORMATION [Abstract]
SEGMENT INFORMATION	NOTE 10. SEGMENT INFORMATION The tables below Three Months Ended September 30, 2016 Corporate USA Brazil Consolidated Revenues $ - $ 8,261 $ 563 $ 8,824 Cost of goods sold - 5,764 1,154 6,918 Gross profit - 2,497 (591 ) 1,906 Depreciation and amortization (in selling, general and administrative) (23 ) (270 ) (16 ) (309 ) Other operating expense (1,784 ) (1,460 ) (493 ) (3,737 ) Income (loss) from operations $ (1,807 ) $ 767 $ (1,100 ) $ (2,140 ) Net income (loss) attributable to RiceBran Technologies shareholders $ (861 ) $ 767 $ (986 ) $ (1,080 ) Interest expense 353 - 393 746 Depreciation (in cost of goods sold) - 216 246 462 Purchases of property - 166 86 252 Nine Months Ended September 30, 2016 Corporate USA Brazil Consolidated Revenues $ - $ 24,793 $ 4,627 $ 29,420 Cost of goods sold - 17,190 6,103 23,293 Gross profit - 7,603 (1,476 ) 6,127 Depreciation and amortization (in selling, general and administrative) (69 ) (854 ) (42 ) (965 ) Other operating expense (5,445 ) (4,160 ) (4,873 ) (14,478 ) Income (loss) from operations $ (5,514 ) $ 2,589 $ (6,391 ) $ (9,316 ) Net income (loss) attributable to RiceBran Technologies shareholders $ (4,955 ) $ 2,589 $ (5,022 ) $ (7,388 ) Interest expense 1,486 - 1,092 2,578 Depreciation (in cost of goods sold) - 619 672 1,291 Purchases of property - 231 229 460 Three Months Ended September 30, 2015 Corporate USA Brazil Consolidated Revenues $ - $ 5,036 $ 3,881 $ 8,917 Cost of goods sold - 3,719 3,141 6,860 Gross profit - 1,317 740 2,057 Depreciation and amortization (in selling, general and administrative) (22 ) (393 ) (11 ) (426 ) Other operating expense (1,067 ) (1,141 ) (769 ) (2,977 ) Loss from operations $ (1,089 ) $ (217 ) $ (40 ) $ (1,346 ) Net income (loss) attributable to RiceBran Technologies shareholders $ (777 ) $ (217 ) $ 470 $ (524 ) Interest expense 348 - 413 761 Depreciation (in cost of goods sold) - 206 220 426 Purchases of property - 72 344 416 Nine Months Ended September 30, 2015 Corporate USA Brazil Consolidated Revenues $ - $ 16,988 $ 12,994 $ 29,982 Cost of goods sold - 11,770 12,864 24,634 Gross profit - 5,218 130 5,348 Depreciation and amortization (in selling, general and administrative) (56 ) (1,181 ) (123 ) (1,360 ) Other operating expense (3,687 ) (3,340 ) (2,790 ) (9,817 ) Income (loss) from operations $ (3,743 ) $ 697 $ (2,783 ) $ (5,829 ) Net income (loss) attributable to RiceBran Technologies shareholders $ (5,260 ) $ 697 $ (2,489 ) $ (7,052 ) Interest expense 999 - 1,435 2,434 Depreciation (in cost of goods sold) - 643 1,193 1,836 Purchases of property - 423 568 991 The tables below Corporate USA Brazil Consolidated As of September 30, 2016 Inventories $ - $ 3,524 $ 351 $ 3,875 Property, net 422 7,787 11,138 19,347 Goodwill - 790 - 790 Intangible assets, net - 476 - 476 Total assets 1,869 16,172 13,185 31,226 As of December 31, 2015 Inventories - 3,302 555 3,857 Property, net 418 8,408 9,502 18,328 Goodwill - 790 2,468 3,258 Intangible assets, net - 1,225 - 1,225 Total assets 3,497 15,260 14,878 33,635 Corporate segment total assets include cash, restricted cash, property and other assets. We review our long-lived assets, including goodwill, for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. During the second quarter of 2016, a number of economic and market conditions arose related to operations of our Brazil segment that impacted raw bran availability and working capital necessary to acquire it, resulting in the Brazil segment taking an estimated goodwill impairment charge of $3.0 million. No modification of the estimated impairment charge was required in the third quarter of 2016 (see Note 5). Additional information on impairment testing of long-lived assets, intangible assets and goodwill can be found in Note 9 of our Annual Report on Form 10-K for the year ended December 31, 2015. The following table presents revenue by geographic area for the three and nine months ended September 30, 2016 and 2015 (in thousands). Three Months Ended Nine Months Ended 2016 2015 2016 2015 United States $ 7,740 $ 6,267 $ 23,113 $ 18,090 Brazil 289 255 3,264 6,157 Other international 795 2,395 3,043 5,735 Total revenues $ 8,824 $ 8,917 $ 29,420 $ 29,982

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	9 Months Ended
	Sep. 30, 2016
FAIR VALUE MEASUREMENTS [Abstract]
FAIR VALUE MEASUREMENTS	NOTE 11. FAIR VALUE MEASUREMENTS The fair value of cash and cash equivalents, accounts and other receivables and accounts payable approximates their carrying value due to their shorter maturities. As of September 30, 2016, the fair value of our Corporate segment debt (Level 3 measurement) approximates the $10.2 million carrying value of that debt, based on current market rates for similar debt with similar maturities. The fair value of our Brazil segment debt (Level 3 measurement) also approximates the $6.8 million carrying value of that debt based on the current market rates for similar debt with similar maturities. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Certain assets and liabilities are presented in the financial statements at fair value. Assets and liabilities measured at fair value on a recurring basis include derivative warrant and conversion liabilities. Assets and liabilities measured at fair value on a non-recurring basis may include property. We assess the inputs used to measure fair value using a three-tier hierarchy based on the extent to which inputs used in measuring fair value are observable in the market: ● Level 1 – inputs include quoted prices for identical instruments and are the most observable. ● Level 2 – inputs include quoted prices for similar assets and observable inputs such as interest rates, currency exchange rates and yield curves. ● Level 3 – inputs are not observable in the market and include management’s judgments about the assumptions market participants would use in pricing the asset or liability. For instruments measured using Level 3 inputs, a reconciliation of the beginning and ending balances is disclosed. The following tables summarize the fair values by input hierarchy of items measured at fair value on a recurring basis on our condensed consolidated balance sheets (in thousands). Level 1 Level 2 Level 3 Total Total liabilities at fair value, as of September 30, 2016 - derivative warrant liabilities $ - $ - $ 2,838 $ 2,838 Total liabilities at fair value, as of December 31, 2015 - derivative warrant liabilities $ - $ - $ 678 $ 678 Warrants accounted for as derivative liabilities are valued using the lattice model each reporting period and the resultant change in fair value is recorded in the condensed consolidated statements of operations. The lattice model requires us to assess the probability of future issuance of equity instruments at a price lower than the current exercise price of the warrants. The risk-free interest rate is determined by reference to the treasury yield curve rate of instruments with the same term as the warrant. Additional assumptions that were used to calculate fair value follow. September 30, 2016 December 31, 2015 Risk-free interest rate 0.6% - 0.9% 0.9% -1.2% (0.8% weighted average) (1.1% weighted average) Expected volatility 69% - 85% 71% - 89% (81% weighted average) (78% weighted average) The following tables summarize the changes in Level 3 items measured at fair value on a recurring basis (in thousands). Total Level 3 Fair Value Fair Value as of Beginning of Period Total Realized and Unrealized Gains (Losses) Issuance of New Instruments Fair Value, at End of Period (1) Nine Months Ended September 30, 2016, derivative warrant liabilities $ (678 ) $ 314 $ (2,474 ) $ (2,838 ) Nine Months Ended September 30, 2015, derivative warrant liabilities $ (955 ) $ 1,211 $ (724 ) $ (468 ) (1) Included in change in fair value of derivative warrant liabilities in our unaudited condensed consolidated statements of operations.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended
	Sep. 30, 2016
RELATED PARTY TRANSACTIONS [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 12. RELATED PARTY TRANSACTIONS Transactions with Baruch Halpern Prior to 2015, entities beneficially owned by Baruch Halpern, a director, invested $2.6 million in our subordinated notes and related warrants, the terms of which were subsequently modified. In the third quarter of 2016, Mr. Halpern purchased an additional $137,500 in subordinated notes from an unrelated note holder. In the three and nine months ended September 30, 2016 and 2015, we expensed and paid $0.1 million and $0.2 million, respectively, of interest on the subordinated notes beneficially owned by Mr. Halpern. In January 2016, we entered into a note payable with Mr. Halpern in the principal amount of $0.3 million and issued Mr. Halpern a warrant to acquire 25,000 shares of common stock (exercise price of $5.25, exercisable immediately and expiring in January 2021). Principal and all interest, accumulating at an 11.75% annual rate, was payable on October 31, 2016. We repaid the note and accumulated interest in full in March 2016. Transactions with W. John Short Prior to 2015, W. John Short, our former chief executive officer and a current director, invested $50,000 in our subordinated notes and related warrants, the terms of which were subsequently modified. In the three and nine months ended September 30, 2016 and 2015, we expensed and paid approximately $2,000 and $5,000, respectively, of interest on the subordinated notes beneficially owned by Mr. Short. Transactions with LF-RB Management, LLC On July 5, 2016, we entered into a Settlement Agreement (Settlement Agreement) with (i) LF-RB Management, LLC, Stephen D. Baksa, Richard Bellofatto, Edward M. Giles, Michael Goose, Gary L. Herman, Larry Hopfenspirger and Richard Jacinto II (collectively, the LF-RB Group) and (ii) Beth Bronner, Ari Gendason and Brent Rosenthal (the LF-RB Designees and together with the LF-RB Group, the Shareholder Group). The LF-RB Group beneficially owns approximately 9.0% of our outstanding stock. Among other things, under the Settlement Agreement we paid the LF-RB Group $50,000 in cash and issued 100,000 shares of our common stock to designees of the LF-RB Group to partially reimburse the LF-RB Group for out-of-pocket legal fees and other expenses incurred by the LF-RB Group in connection with its solicitation of proxies to elect its designees to the Board at the 2016 Annual Meeting of Shareholders.

FAILURE TO COMPLY WITH NASDAQ L

FAILURE TO COMPLY WITH NASDAQ LISTING REQUIREMENTS	9 Months Ended
	Sep. 30, 2016
FAILURE TO COMPLY WITH NASDAQ LISTING REQUIREMENTS [Abstract]
FAILURE TO COMPLY WITH NASDAQ LISTING REQUIREMENTS	NOTE 13. FAILURE TO COMPLY WITH NASDAQ LISTING REQUIREMENTS On August 18, 2016, we received a notification letter from The Nasdaq Stock Market LLC ("Nasdaq") indicating that we have failed to comply with the minimum stockholders' equity requirement of Nasdaq Listing Rule 5550(b)(1). Nasdaq Listing Rule 5550(b)(1) requires that companies listed on the Nasdaq Capital Market maintain a minimum of $2,500,000 in stockholders' equity for continued listing. Our Quarterly Report on Form 10-Q for the quarter ended June 30, 2016 reported stockholders' equity (deficit) of ($36,000). The notification letter has no immediate effect on our listing on the Nasdaq Capital Market. We submitted our plan to regain compliance to Nasdaq on October 5, 2016, and received a follow-up request for additional information, which we submitted on October 28, 2016. If our plan to regain compliance is accepted, Nasdaq may grant an extension of up to 180 calendar days from the date of the notification letter to regain compliance. If our plan to regain compliance is not accepted, we will have the opportunity to appeal that decision to a Hearings Panel. There can be no assurance that our plan will be accepted or that, if it is, we will be able to regain compliance with the applicable Nasdaq listing requirements.

SEVERANCE ACTIVITIES

SEVERANCE ACTIVITIES	9 Months Ended
	Sep. 30, 2016
SEVERANCE ACTIVITIES [Abstract]
SEVERANCE ACTIVITIES	NOTE 14. SEVERANCE ACTIVITIES On August 27, 2016, W. John Short’s employment as our chief executive officer was terminated. Mr. Short continues to serve on the Company’s Board of Directors. The Company and Mr. Short have been unable to agree upon the severance payments owed to Mr. Short under his employment agreement with the Company. In order to resolve this dispute, on September 22, 2016, we filed an Arbitration Demand for Declaratory Relief (the “Demand”) against Mr. Short. In the Demand, we seek a determination and declaration resolving all disputes between the Company and Mr. Short, including those relating to the amounts owed to Mr. Short in connection with his employment termination. The Demand was filed with the American Arbitration Association in Phoenix, Arizona. We have accrued estimated severance payments in the amount of $700,000. We expect to pay the final settlement within the next 12 months and, therefore, we have included the amount in accrued salary, wages and benefits in our condensed consolidated balance sheet as of September 30, 2016.

CHIEF EXECUTIVE OFFICER APPOINT

CHIEF EXECUTIVE OFFICER APPOINTMENT	9 Months Ended
	Sep. 30, 2016
CHIEF EXECUTIVE OFFICER APPOINTMENT [Abstract]
CHIEF EXECUTIVE OFFICER APPOINTMENT	NOTE 15. CHIEF EXECUTIVE OFFICER APPOINTMENT On August 27, 2016, Robert Smith, PhD, 55, was appointed interim Chief Executive Officer of RiceBran Technologies. Dr. Smith has served as our Chief Operating Officer since June 2016. Dr. Smith served as the Company’s senior vice president of operations and R&D from November 2014 to June 2016, as senior vice president of sales and business development from November 2013 to November 2014 and as senior vice president of business development from March 2012 to November 2013. Dr. Smith brings over 20 years’ experience managing research and development and business development in the Ag-biotech industry. He served as director of business development at HerbalScience Group from 2007 to 2010 and worked at Affynis LLC from 2010 to 2012 as a consultant. Dr. Smith has also served as director of research and developments at Global Protein Products Inc. and PhycoGen Inc., and was project leader at Dekalb Genetics, a Monsanto Company. Dr. Smith was a research assistant professor at the Ag-Biotech Center at Rutgers University and did his post-doctoral work in plant molecular biology at the University of Missouri-Columbia. He holds a doctor of philosophy degree in molecular genetics and cell biology from the University of Chicago and a bachelor of arts degree in biology from the University of Chicago.

BASIS OF PRESENTATION (Policies

BASIS OF PRESENTATION (Policies)	9 Months Ended
	Sep. 30, 2016
BASIS OF PRESENTATION [Abstract]
Recent Accounting Guidance	Recent Accounting Guidance Recent accounting guidance not yet adopted In August 2014, the Financial Accounting Standards Board (FASB) issued guidance which requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of the date the financial statements are issued and provides guidance on determining when and how to disclose going concern uncertainties in the financial statements. Certain disclosures will be required if conditions give rise to substantial doubt about an entity’s ability to continue as a going concern The guidance applies to all entities and is effective for annual periods ending after December 15, 2016, and interim periods thereafter, with early adoption permitted. We will adopt this standard in the fourth quarter of 2016, and we do not expect the adoption to have a material effect on our results of operations. In May 2014, the FASB issued guidance on revenue from contracts with customers to clarify the principles for recognizing revenue and develop a common revenue standard for GAAP and International Financial Reporting Standards. Under the new guidance, an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services, applying the following steps: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. The guidance is effective for our annual and interim periods beginning in 2018. Early adoption is permitted. We have not yet determined the impact that the new guidance will have on our results of operations and financial position and have not yet determined if we will early adopt the standard. In February 2016, the FASB issued guidance which changes the accounting for leases. Under prior GAAP, the recognition, measurement and presentation of expenses and cash flows arising from a lease for us as a lessee depend primarily on the lease’s classification as a finance or operating lease. For both types of leases, lessees will recognize a right-of-use asset and a lease liability. For capital or finance leases, lessees will recognize amortization of the right-of-use asset separately from interest expense on the lease liability. The guidance is effective for our annual and interim periods beginning in 2019 and must be adopted on a modified retrospective approach. Early adoption is allowed. We have not yet determined the impact that the new guidance will have on our results of operations, financial position and cash flows and have not yet determined if we will early adopt the standard. In March 2016, the FASB issued new guidance that changes the accounting for certain aspects of share-based payments to employees. The new guidance requires excess tax benefits and tax deficiencies to be recorded in the income statement when the awards vest or are settled. In addition, cash flows related to excess tax benefits will no longer be separately classified as a financing activity apart from other income tax cash flows. The guidance also allows us to repurchase more of an employee’s shares for tax withholding purposes without triggering liability accounting, clarifies that all cash payments made on an employee’s behalf for withheld shares should be presented as a financing activity on our cash flows statement, and provides an accounting policy election to account for forfeitures as they occur. The guidance is effective for our annual and interim periods beginning in 2017 with early adoption permitted. We plan to adopt the standard in the first quarter of 2017 and change our accounting policy to recognize forfeitures as they occur. This change will not have a material effect on our results of operations as we currently do not apply an estimated forfeiture rate to restricted stock awards to our officers and directors. Additionally, most of our outstanding stock option awards vest on a monthly basis over the vesting period (generally three or four years). As these awards do not have performance conditions, the expense is recognized each month on a straight-line basis and excludes the effect of the estimated forfeiture rate as there is no risk of expensing awards that would be subsequently forfeited prior to vesting. In June 2016, the FASB issued a new credit loss standard that replaces the incurred loss impairment methodology in current GAAP. The new impairment model requires immediate recognition of estimated credit losses expected to occur for most financial assets and certain other instruments. It is effective for annual reporting periods beginning after December 15, 2019 and interim periods within those annual periods. Early adoption for fiscal years beginning after December 15, 2018 is permitted. Entities will apply the standard’s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first effective reporting period. We have not yet determined the impact that the new guidance will have on our results of operations, financial position and cash flows and have not yet determined if we will early adopt the standard Recently adopted accounting guidance In February 2015, the FASB issued guidance which makes targeted amendments to current consolidation guidance. Among other things, the standard changes the manner in which we would assess one of the characteristics of variable interest entities (VIEs) and introduces a separate analysis specific to limited partnerships and similar entities (such as Nutra SA, LLC) for assessing if the equity holders at risk lack decision making authority. Limited partnerships and similar entities will be a VIE unless the limited partners hold substantive kick-out rights or participating rights. A right to liquidate an entity is akin to a kick-out right. Guidance for limited partnerships under the voting model has been eliminated. A limited partner and similar partners with a controlling financial interest obtained through substantive kick-out rights would consolidate a limited partnership or similar entity. Upon adoption in the first quarter of 2016, there was no impact on our financial position or results of operations. Specifically, under the new guidance, we continue to be the primary beneficiary of Nutra SA, LLC.

LOSS PER SHARE (EPS) (Tables)

LOSS PER SHARE (EPS) (Tables)	9 Months Ended
	Sep. 30, 2016
LOSS PER SHARE (EPS) [Abstract]
Reconciliations of numerators and denominators in EPS computations	Below are reconciliations of the numerators and denominators in the EPS computations for the three and nine months ended September 30, 2016 and 2015. Three Months Ended Nine Months Ended 2016 2015 2016 2015 NUMERATOR (in thousands): Basic and diluted - net loss attributable to RiceBran Technologies shareholders $ (1,080 ) $ (524 ) $ (7,388 ) $ (7,052 ) Dividend on preferred stock--beneficial conversion feature - - (551 ) - Basic and diluted - net loss attributable to RiceBran Technologies common shareholders $ (1,080 ) $ (524 ) $ (7,939 ) $ (7,052 ) DENOMINATOR: Basic EPS - weighted average number of common shares outstanding 9,397,255 9,222,150 9,281,942 9,181,607 Effect of dilutive securities outstanding - - - - Diluted EPS - weighted average number of shares outstanding 9,397,255 9,222,150 9,281,942 9,181,607 Number of shares of common stock which could be purchased with weighted average outstanding securities not included in diluted EPS because effect would be antidilutive: Stock options 340,037 341,315 350,203 288,751 Warrants 10,842,006 7,093,628 10,132,045 6,808,513 Nonvested stock 1,114,747 300,779 1,038,019 212,156 Convertible preferred stock 2,000,000 - 1,611,722 -

GOODWILL (Tables)

GOODWILL (Tables)	9 Months Ended
	Sep. 30, 2016
GOODWILL [Abstract]
Summary of goodwill activity	The following table reflects goodwill allocated to each reporting segment at September 30, 2016 2015 (in thousands) USA Segment Brazil Segment Total Goodwill Balance, December 31, 2015 $ 790 $ 2,468 $ 3,258 Goodwill impairment - (3,024 ) (3,024 ) Effect of change in exchange rates - 556 556 Balance, September 30, 2016 $ 790 $ - $ 790

REDEEMABLE NONCONTROLLING INT25

REDEEMABLE NONCONTROLLING INTEREST IN NUTRA SA (Tables)	9 Months Ended
	Sep. 30, 2016
REDEEMABLE NONCONTROLLING INTEREST IN NUTRA SA [Abstract]
Summary of the carrying amounts included in consolidated balance sheets	A summary of the carrying amounts of Nutra SA balances included in our condensed consolidated balance sheets follows (in thousands). September 30, December 31, 2016 2015 Cash and cash equivalents $ 67 $ 104 Other current assets (restricted $222 and $1,003) 919 2,760 Property and equipment, net (restricted $2,449 and $2,102) 11,138 9,502 Goodwill and intangibles, net - 2,468 Other noncurrent assets 1,061 43 Total assets $ 13,185 $ 14,877 Current liabilities $ 7,867 $ 4,647 Current portion of long-term debt (nonrecourse) 6,849 2,750 Long-term debt, less current portion (nonrecourse) - 3,553 Total liabilities $ 14,716 $ 10,950
Summary of changes in redeemable noncontrolling interest	A summary of changes in redeemable noncontrolling interest in Nutra SA for the three and nine months ended September 30, 2016 and 2015 (in thousands) follows. Three Months Ended Nine Months Ended 2016 2015 2016 2015 Redeemable noncontrolling interest in Nutra SA, beginning of period $ (1,599 ) $ 862 $ 69 $ 2,643 Investors' interest in net loss of Nutra SA (470 ) (1,046 ) (2,416 ) (2,122 ) Investors' interest in accumulated other comprehensive loss of Nutra SA (60 ) (482 ) 218 (900 ) Investors' purchase of additional units 200 - 200 - Accumulated Yield classified as other current liability - 861 - 574 Redeemable noncontrolling interest in Nutra SA, end of period $ (1,929 ) $ 195 $ (1,929 ) $ 195 Investors' average interest in Nutra SA during the period 32.5 % 32.1 % 32.2 % 33.2 % Investors' interest in Nutra SA at the end of the period 32.7 % 32.1 % 32.7 % 32.1 %

DEBT (Tables)

DEBT (Tables)	9 Months Ended
	Sep. 30, 2016
DEBT [Abstract]
Current and long-term debt	The following table summarizes current and long-term portions of debt (in thousands): September 30, December 31, 2016 2015 Corporate segment: Senior revolving loan $ 2,866 $ 1,617 Senior term loan, net 946 1,407 Subordinated notes, net, maturing in May 2018, principal $6.3 million 6,310 6,310 Subordinated notes, net, paid in July 2016, principal $0 - 205 Other 74 116 10,196 9,655 Brazil segment: Capital expansion loans 2,417 2,067 Working capital lines of credit 584 828 Advances on customer export orders 1,113 1,310 Special tax programs 2,703 2,064 Other 32 34 6,849 6,303 Total debt 17,045 15,958 Current portion 11,982 5,050 Long-term portion $ 5,063 $ 10,908

EQUITY, SHARE-BASED COMPENSAT27

EQUITY, SHARE-BASED COMPENSATION AND WARRANTS (Tables)	9 Months Ended
	Sep. 30, 2016
EQUITY, SHARE-BASED COMPENSATION AND WARRANTS [Abstract]
Summary of equity activity	A summary of equity activity for the nine months ended September 30, 2016, (in thousands, except share data) follows. Common Stock Accumulated Accumulated Deficit Attributable to Noncontrolling Interest in Accumulated Other Comprehensive Total (Deficit) Shares Amount Deficit Nutra SA Loss Equity Balance, December 31, 2015 9,537,415 $ 262,895 $ (250,738 ) $ - $ (4,889 ) $ 7,268 Share-based compensation, employees and directors - 619 - - - 619 Issuance of preferred stock and warrants - (447 ) - - - (447 ) Dividend on preferred stock--beneficial conversion feature - 551 (551 ) - - - Issuance of common stock to supplier 950,000 - - - - - Other 313,271 213 - - - 213 Accumulated deficit attributable to noncontrolling interest in Nutra SA - - - (1,929 ) - (1,929 ) Foreign currency translation - - - - 474 474 Net loss - - (7,388 ) - - (7,388 ) Balance, September 30, 2016 10,800,686 $ 263,831 $ (258,677 ) $ (1,929 ) $ (4,415 ) $ (1,190 )
Summary of warrant activity	A summary of warrant activity for the nine months ended September 30, 2016, follows. Equity Warrants Liability Warrants Shares Underlying Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Shares Underlying Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Outstanding, December 31, 2015 6,367,139 $ 5.78 3.4 726,489 $ 5.24 2.9 Issued - NA 2,685,000 2.03 4.5 Impact of anti-dilution clauses - NA 1,063,379 1.50 1.3 Exercised - NA - NA Forfeited, expired or cancelled - NA - NA Outstanding, September 30, 2016 6,367,139 $ 5.78 2.7 4,474,868 $ 1.82 3.6 Exercisable, September 30, 2016 6,367,139 $ 5.78 2.7 4,474,868 $ 1.82 3.6

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	9 Months Ended
	Sep. 30, 2016
SEGMENT INFORMATION [Abstract]
Segment information identified and reconciliations of segment information to total consolidated information	The tables below Three Months Ended September 30, 2016 Corporate USA Brazil Consolidated Revenues $ - $ 8,261 $ 563 $ 8,824 Cost of goods sold - 5,764 1,154 6,918 Gross profit - 2,497 (591 ) 1,906 Depreciation and amortization (in selling, general and administrative) (23 ) (270 ) (16 ) (309 ) Other operating expense (1,784 ) (1,460 ) (493 ) (3,737 ) Income (loss) from operations $ (1,807 ) $ 767 $ (1,100 ) $ (2,140 ) Net income (loss) attributable to RiceBran Technologies shareholders $ (861 ) $ 767 $ (986 ) $ (1,080 ) Interest expense 353 - 393 746 Depreciation (in cost of goods sold) - 216 246 462 Purchases of property - 166 86 252 Nine Months Ended September 30, 2016 Corporate USA Brazil Consolidated Revenues $ - $ 24,793 $ 4,627 $ 29,420 Cost of goods sold - 17,190 6,103 23,293 Gross profit - 7,603 (1,476 ) 6,127 Depreciation and amortization (in selling, general and administrative) (69 ) (854 ) (42 ) (965 ) Other operating expense (5,445 ) (4,160 ) (4,873 ) (14,478 ) Income (loss) from operations $ (5,514 ) $ 2,589 $ (6,391 ) $ (9,316 ) Net income (loss) attributable to RiceBran Technologies shareholders $ (4,955 ) $ 2,589 $ (5,022 ) $ (7,388 ) Interest expense 1,486 - 1,092 2,578 Depreciation (in cost of goods sold) - 619 672 1,291 Purchases of property - 231 229 460 Three Months Ended September 30, 2015 Corporate USA Brazil Consolidated Revenues $ - $ 5,036 $ 3,881 $ 8,917 Cost of goods sold - 3,719 3,141 6,860 Gross profit - 1,317 740 2,057 Depreciation and amortization (in selling, general and administrative) (22 ) (393 ) (11 ) (426 ) Other operating expense (1,067 ) (1,141 ) (769 ) (2,977 ) Loss from operations $ (1,089 ) $ (217 ) $ (40 ) $ (1,346 ) Net income (loss) attributable to RiceBran Technologies shareholders $ (777 ) $ (217 ) $ 470 $ (524 ) Interest expense 348 - 413 761 Depreciation (in cost of goods sold) - 206 220 426 Purchases of property - 72 344 416 Nine Months Ended September 30, 2015 Corporate USA Brazil Consolidated Revenues $ - $ 16,988 $ 12,994 $ 29,982 Cost of goods sold - 11,770 12,864 24,634 Gross profit - 5,218 130 5,348 Depreciation and amortization (in selling, general and administrative) (56 ) (1,181 ) (123 ) (1,360 ) Other operating expense (3,687 ) (3,340 ) (2,790 ) (9,817 ) Income (loss) from operations $ (3,743 ) $ 697 $ (2,783 ) $ (5,829 ) Net income (loss) attributable to RiceBran Technologies shareholders $ (5,260 ) $ 697 $ (2,489 ) $ (7,052 ) Interest expense 999 - 1,435 2,434 Depreciation (in cost of goods sold) - 643 1,193 1,836 Purchases of property - 423 568 991
Segment information for selected balance sheet accounts	The tables below Corporate USA Brazil Consolidated As of September 30, 2016 Inventories $ - $ 3,524 $ 351 $ 3,875 Property, net 422 7,787 11,138 19,347 Goodwill - 790 - 790 Intangible assets, net - 476 - 476 Total assets 1,869 16,172 13,185 31,226 As of December 31, 2015 Inventories - 3,302 555 3,857 Property, net 418 8,408 9,502 18,328 Goodwill - 790 2,468 3,258 Intangible assets, net - 1,225 - 1,225 Total assets 3,497 15,260 14,878 33,635
Revenue by geographic area	The following table presents revenue by geographic area for the three and nine months ended September 30, 2016 and 2015 (in thousands). Three Months Ended Nine Months Ended 2016 2015 2016 2015 United States $ 7,740 $ 6,267 $ 23,113 $ 18,090 Brazil 289 255 3,264 6,157 Other international 795 2,395 3,043 5,735 Total revenues $ 8,824 $ 8,917 $ 29,420 $ 29,982

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	9 Months Ended
	Sep. 30, 2016
FAIR VALUE MEASUREMENTS [Abstract]
Fair values by input hierarchy of items measured at fair value on a recurring basis	The following tables summarize the fair values by input hierarchy of items measured at fair value on a recurring basis on our condensed consolidated balance sheets (in thousands). Level 1 Level 2 Level 3 Total Total liabilities at fair value, as of September 30, 2016 - derivative warrant liabilities $ - $ - $ 2,838 $ 2,838 Total liabilities at fair value, as of December 31, 2015 - derivative warrant liabilities $ - $ - $ 678 $ 678
Additional assumptions used to calculate fair value	Additional assumptions that were used to calculate fair value follow. September 30, 2016 December 31, 2015 Risk-free interest rate 0.6% - 0.9% 0.9% -1.2% (0.8% weighted average) (1.1% weighted average) Expected volatility 69% - 85% 71% - 89% (81% weighted average) (78% weighted average)
Changes in level 3 items measured at fair value	The following tables summarize the changes in Level 3 items measured at fair value on a recurring basis (in thousands). Total Level 3 Fair Value Fair Value as of Beginning of Period Total Realized and Unrealized Gains (Losses) Issuance of New Instruments Fair Value, at End of Period (1) Nine Months Ended September 30, 2016, derivative warrant liabilities $ (678 ) $ 314 $ (2,474 ) $ (2,838 ) Nine Months Ended September 30, 2015, derivative warrant liabilities $ (955 ) $ 1,211 $ (724 ) $ (468 ) (1) Included in change in fair value of derivative warrant liabilities in our unaudited condensed consolidated statements of operations.

BASIS OF PRESENTATION (Details)

BASIS OF PRESENTATION (Details) - Stock Options [Member]	9 Months Ended
	Sep. 30, 2016
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	4 years
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	3 years

LIQUIDITY, GOING CONCERN AND 31

LIQUIDITY, GOING CONCERN AND MANAGEMENT'S PLAN (Details) - USD ($) $ in Thousands	1 Months Ended				3 Months Ended		9 Months Ended		12 Months Ended
	Oct. 31, 2016	Mar. 31, 2016	Feb. 29, 2016	May 31, 2015	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2014
Line of Credit Facility [Abstract]
Loss on extinguishment					$ 0	$ 0	$ 0	$ (1,904)
Proceeds from preference stock and warrants			$ 2,600				2,554	$ 0
Short-term Note [Member]
Line of Credit Facility [Abstract]
Amount paid from a related party		$ 300
Senior Secured Credit Facility [Member]
Line of Credit Facility [Abstract]
Percentage of principal due				97.00%
Loss on extinguishment				$ (1,900)
Revolving Credit Facility [Member]
Line of Credit Facility [Abstract]
Amount held in escrow		1,900
Term Loan [Member]
Line of Credit Facility [Abstract]
Repayment of term loan		$ 1,000
USA [Member] | Senior Secured Credit Facility [Member]
Line of Credit Facility [Abstract]
Principal amount of senior secured credit facility agreement				8,000
USA [Member] | Revolving Credit Facility [Member]
Line of Credit Facility [Abstract]
Maximum borrowing amount				3,500
USA [Member] | Term Loan [Member]
Line of Credit Facility [Abstract]
Initial amount of term loan				$ 2,500
Period for term loan increase				2 years
USA [Member] | Term Loan [Member] | Maximum [Member]
Line of Credit Facility [Abstract]
Maximum borrowing amount				$ 2,000
Irgovel [Member] | Subsequent Event [Member]
Line of Credit Facility [Abstract]
Minority partner contribution amount	$ 1,200
Investors [Member] | Nutra SA [Member]
Noncontrolling Interest [Abstract]
Additional investments							1,100		$ 3,600	$ 10,300
Additional contributions without approval of lender					$ 400		$ 400

BUSINESS (Details)

BUSINESS (Details)	9 Months Ended
	Sep. 30, 2016Segment
BUSINESS [Abstract]
Number of reportable business segments	2

LOSS PER SHARE (EPS) (Details)

LOSS PER SHARE (EPS) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
NUMERATOR [Abstract]
Basic and diluted - net loss attributable to RiceBran Technologies shareholders	$ (1,080)	$ (524)	$ (7,388)	$ (7,052)
Dividend on preferred stock-beneficial conversion feature	0	0	(551)	0
Net loss attributable to RiceBran Technologies common shareholders	$ (1,080)	$ (524)	$ (7,939)	$ (7,052)
DENOMINATOR [Abstract]
Basic EPS - weighted average number of shares outstanding (in shares)	9,397,255	9,222,150	9,281,942	9,181,607
Effect of dilutive securities outstanding (in shares)	0	0	0	0
Diluted EPS - weighted average number of shares outstanding (in shares)	9,397,255	9,222,150	9,281,942	9,181,607
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of shares of common stock which could be purchased with weighted average outstanding securities not included in diluted EPS because effect would be antidilutive (in shares)	340,037	341,315	350,203	288,751
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of shares of common stock which could be purchased with weighted average outstanding securities not included in diluted EPS because effect would be antidilutive (in shares)	10,842,006	7,093,628	10,132,045	6,808,513
Nonvested Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of shares of common stock which could be purchased with weighted average outstanding securities not included in diluted EPS because effect would be antidilutive (in shares)	1,114,747	300,779	1,038,019	212,156
Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of shares of common stock which could be purchased with weighted average outstanding securities not included in diluted EPS because effect would be antidilutive (in shares)	2,000,000	0	1,611,722	0

GOODWILL (Details)

GOODWILL (Details) - USD ($) $ in Thousands	3 Months Ended			9 Months Ended
	Sep. 30, 2016	Jun. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Goodwill [Roll Forward]
Goodwill, beginning of period				$ 3,258
Goodwill impairment	$ 0		$ 0	(3,024)	$ 0
Effect of change in exchange rates				556
Goodwill, end of period	790			790
USA Segment [Member]
Goodwill [Roll Forward]
Goodwill, beginning of period				790
Goodwill impairment				0
Effect of change in exchange rates				0
Goodwill, end of period	790			790
Brazil Segment [Member]
Goodwill [Roll Forward]
Goodwill, beginning of period				2,468
Goodwill impairment	0	$ (3,024)		(3,024)
Effect of change in exchange rates				556
Goodwill, end of period	$ 0			$ 0

REDEEMABLE NONCONTROLLING INT35

REDEEMABLE NONCONTROLLING INTEREST IN NUTRA SA (Details) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	Oct. 31, 2016USD ($)	Sep. 30, 2016USD ($)RepresentativeInvestor	Sep. 30, 2015USD ($)	Sep. 30, 2016USD ($)RepresentativeInvestor	Sep. 30, 2015USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)
Summary of carrying amounts included in consolidated balance sheets [Abstract]
Cash and cash equivalents		$ 2,199	$ 1,523	$ 2,199	$ 1,523	$ 1,070	$ 3,610
Other current assets (restricted $222 and $1,003)		749		749		895
Property and equipment, net (restricted $2,449 and $2,102)		19,347		19,347		18,328
Other noncurrent assets		122		122		103
Current liabilities		23,930		23,930		14,678
Current portion of long-term debt (nonrecourse)		11,982		11,982		5,050
Long-term debt, less current portion (nonrecourse)		5,063		5,063		10,908
Summary of changes for redeemable noncontrolling interest [Roll Forward]
Redeemable noncontrolling interest in Nutra SA, beginning of period	$ 0			69
Investors' purchase of additional units				200	0
Redeemable noncontrolling interest in Nutra SA, end of period		0		0
Irgovel [Member] | Minimum [Member]
Summary of changes for redeemable noncontrolling interest [Roll Forward]
EBITDA triggering default status				4,000
Nutra SA [Member]
Summary of carrying amounts included in consolidated balance sheets [Abstract]
Cash and cash equivalents		67		67		104
Other current assets (restricted $222 and $1,003)		919		919		2,760
Property and equipment, net (restricted $2,449 and $2,102)		11,138		11,138		9,502
Goodwill and intangibles, net		0		0		2,468
Other noncurrent assets		1,061		1,061		43
Total assets		13,185		13,185		14,877
Current liabilities		7,867		7,867		4,647
Current portion of long-term debt (nonrecourse)		6,849		6,849		2,750
Long-term debt, less current portion (nonrecourse)		0		0		3,553
Total liabilities		14,716		14,716		10,950
Restricted portion of other current assets		222		222		1,003
Variable interest entity restricted portion of property, net		2,449		2,449		$ 2,102
Investors' purchase of additional units of Nutra SA attributable to the parent				1,100
Escrow funds distribution		1,700
Summary of changes for redeemable noncontrolling interest [Roll Forward]
Redeemable noncontrolling interest in Nutra SA, beginning of period	(1,929)	(1,599)	862	69	2,643
Investors' interest in net loss of Nutra SA		(470)	(1,046)	(2,416)	(2,122)
Investors' interest in accumulated other comprehensive loss of Nutra SA		(60)	(482)	218	(900)
Investors' purchase of additional units		200	0	200	0
Accumulated Yield classified as other current liability		0	861	0	574
Redeemable noncontrolling interest in Nutra SA, end of period		$ (1,929)	$ 195	$ (1,929)	$ 195
Investors' average interest in Nutra SA during the period		32.50%	32.10%	32.20%	33.20%
Investors' interest in Nutra SA at the end of the period		32.70%	32.10%	32.70%	32.10%
Number of representatives on management committee | Representative		3		3
Number of Investors on Management Committee | Investor		2		2
Number of representatives on management committee upon default | Representative		2		2
Number of Investors on Management Committee Upon Default | Investor		3		3
Nutra SA [Member] | Subsequent Event [Member]
Summary of changes for redeemable noncontrolling interest [Roll Forward]
Investors' purchase of additional units	$ 1,200
Nutra SA [Member] | Investors [Member]
Summary of changes for redeemable noncontrolling interest [Roll Forward]
Drag along right termination amount		$ 50,000		$ 50,000
Nutra SA [Member] | Investors [Member] | Maximum [Member]
Summary of changes for redeemable noncontrolling interest [Roll Forward]
Percentage of outstanding common stock issued		49.00%

DEBT (Details)

DEBT (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		3 Months Ended	9 Months Ended
	Mar. 31, 2016	Feb. 29, 2016	Mar. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Jan. 31, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Total debt				$ 17,045			$ 15,958
Current portion				11,982			5,050
Long-term portion				$ 5,063			10,908
Expiration January, 2021 [Member] | Warrants [Member]
Debt Instrument [Line Items]
Exercise price of warrants (in dollars per share)				$ 1.60	$ 1.85	$ 5.25
Director [Member] | Expiration January, 2021 [Member] | Warrants [Member]
Debt Instrument [Line Items]
Warrants to purchase shares of common stock (in shares)						25,000
Exercise price of warrants (in dollars per share)						$ 5.25
Director [Member] | Subordinated Notes, Net [Member]
Debt Instrument [Line Items]
Due to related parties				$ 2,600
Director [Member] | Note Payable [Member]
Debt Instrument [Line Items]
Due to related parties						$ 300
Director [Member] | Note Payable [Member] | Expiration January, 2021 [Member]
Debt Instrument [Line Items]
Due to related parties						$ 300
Corporate Segment [Member]
Debt Instrument [Line Items]
Total debt				10,196			9,655
Corporate Segment [Member] | Senior Revolving Loan [Member]
Debt Instrument [Line Items]
Total debt				$ 2,866			1,617
Average monthly adjusted EBITDA, calculation period				3 months
Corporate Segment [Member] | Senior Revolving Loan [Member] | Minimum [Member]
Debt Instrument [Line Items]
Credit facility, liquidity covenant amount		$ 1,500
Credit facility, covenant amount available in cash		800
Average monthly adjusted EBITDA		$ 100
Corporate Segment [Member] | Senior Revolving Loan [Member] | Amendment Agreement [Member]
Debt Instrument [Line Items]
Amount paid in consideration of amendment expenses				$ 200
Corporate Segment [Member] | Senior Revolving Loan [Member] | Amendment Agreement [Member] | Minimum [Member]
Debt Instrument [Line Items]
Credit facility, liquidity covenant amount				1,300
Credit facility, covenant amount available in cash				500
Corporate Segment [Member] | Senior Term Loan, Net [Member]
Debt Instrument [Line Items]
Total debt				946			1,407
Repayment of senior term note	$ 1,000
Debt issuance costs written off to interest expense			$ 200
Amount paid in consideration of amendment expenses	$ 100		$ 100
Corporate Segment [Member] | Subordinated Notes, Net [Member] | Notes Due May 2018 [Member]
Debt Instrument [Line Items]
Total debt				6,310			6,310
Principal amount outstanding of subordinated notes				$ 6,300
Maturity date of note				May 31, 2018
Corporate Segment [Member] | Subordinated Notes, Net [Member] | Notes Due July 2016 [Member]
Debt Instrument [Line Items]
Total debt				$ 0			205
Principal amount outstanding of subordinated notes				$ 0
Maturity date of note				Jul. 31, 2016
Corporate Segment [Member] | Other [Member]
Debt Instrument [Line Items]
Total debt				$ 74			116
Brazil Segment [Member]
Debt Instrument [Line Items]
Total debt				6,849			6,303
Brazil Segment [Member] | Capital Expansion Loans [Member]
Debt Instrument [Line Items]
Total debt				2,417			2,067
Brazil Segment [Member] | Working Capital Lines of Credit [Member]
Debt Instrument [Line Items]
Total debt				584			828
Brazil Segment [Member] | Advances on Customer Export Orders [Member]
Debt Instrument [Line Items]
Total debt				1,113			1,310
Brazil Segment [Member] | Special Tax Programs [Member]
Debt Instrument [Line Items]
Total debt				2,703			2,064
Brazil Segment [Member] | Other [Member]
Debt Instrument [Line Items]
Total debt				$ 32			$ 34

EQUITY, SHARE-BASED COMPENSAT37

EQUITY, SHARE-BASED COMPENSATION AND WARRANTS (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance at beginning of period			$ 7,268
Balance at beginning of period (in shares)			9,537,415
Share-based compensation, employees and directors			$ 619
Issuance of preferred stock and warrants			(447)
Dividend on preferred stock--beneficial conversion feature			0
Issuance of common stock to supplier			0
Other			213
Accumulated deficit attributable to noncontrolling interest in Nutra SA			(1,929)
Foreign currency translation			474
Net loss	$ (1,080)	$ (524)	(7,388)	$ (7,052)
Balance at end of period	$ (1,190)		$ (1,190)
Balance at end of period (in shares)	10,800,686		10,800,686
Common Stock [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance at beginning of period			$ 262,895
Balance at beginning of period (in shares)			9,537,415
Share-based compensation, employees and directors			$ 619
Share-based compensation, employees and directors (in shares)			0
Issuance of preferred stock and warrants			$ (447)
Issuance of preferred stock and warrants (in shares)			0
Dividend on preferred stock--beneficial conversion feature			$ 551
Issuance of common stock to supplier			$ 0
Issuance of common stock to supplier (in shares)			950,000
Other			$ 213
Other (in shares)			313,271
Accumulated deficit attributable to noncontrolling interest in Nutra SA			$ 0
Foreign currency translation			0
Net loss			0
Balance at end of period	$ 263,831		$ 263,831
Balance at end of period (in shares)	10,800,686		10,800,686
Accumulated Deficit [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance at beginning of period			$ (250,738)
Share-based compensation, employees and directors			0
Issuance of preferred stock and warrants			0
Dividend on preferred stock--beneficial conversion feature			(551)
Issuance of common stock to supplier			0
Other			0
Accumulated deficit attributable to noncontrolling interest in Nutra SA			0
Foreign currency translation			0
Net loss			(7,388)
Balance at end of period	$ (258,677)		(258,677)
Accumulated Deficit Attributable to Noncontrolling Interest in Nutra SA [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance at beginning of period			0
Share-based compensation, employees and directors			0
Issuance of preferred stock and warrants			0
Dividend on preferred stock--beneficial conversion feature			0
Issuance of common stock to supplier			0
Other			0
Accumulated deficit attributable to noncontrolling interest in Nutra SA			(1,929)
Foreign currency translation			0
Net loss			0
Balance at end of period	(1,929)		(1,929)
Accumulated Other Comprehensive Loss [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance at beginning of period			(4,889)
Share-based compensation, employees and directors			0
Issuance of preferred stock and warrants			0
Dividend on preferred stock--beneficial conversion feature			0
Issuance of common stock to supplier			0
Other			0
Accumulated deficit attributable to noncontrolling interest in Nutra SA			0
Foreign currency translation			474
Net loss			0
Balance at end of period	$ (4,415)		$ (4,415)

EQUITY, SHARE-BASED COMPENSAT38

EQUITY, SHARE-BASED COMPENSATION AND WARRANTS, Warrant Activity (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Equity Warrant [Member]
Shares Under Warrants [Roll Forward]
Outstanding at beginning of period (in shares)	6,367,139
Issued (in shares)	0
Impact of anti-dilution clauses (in shares)	0
Exercised (in shares)	0
Forfeited, expired or cancelled (in shares)	0
Outstanding at end of period (in shares)	6,367,139	6,367,139
Exercisable at end of period (in shares)	6,367,139
Equity and Liability Warrants Outstanding, Weighted Average Exercise Price [Roll Forward]
Outstanding at beginning of period (in dollars per share)	$ 5.78
Outstanding at end of period (in dollars per share)	5.78	$ 5.78
Exercisable at end of period (in dollars per share)	$ 5.78
Equity and Liability Warrants, Additional Disclosures [Abstract]
Outstanding, weighted average remaining contractual life	2 years 8 months 12 days	3 years 4 months 24 days
Exercisable, weighted average remaining contractual life	2 years 8 months 12 days
Liability Warrant [Member]
Shares Under Warrants [Roll Forward]
Outstanding at beginning of period (in shares)	726,489
Issued (in shares)	2,685,000
Impact of anti-dilution clauses (in shares)	1,063,379
Exercised (in shares)	0
Forfeited, expired or cancelled (in shares)	0
Outstanding at end of period (in shares)	4,474,868	726,489
Exercisable at end of period (in shares)	4,474,868
Equity and Liability Warrants Outstanding, Weighted Average Exercise Price [Roll Forward]
Outstanding at beginning of period (in dollars per share)	$ 5.24
Issued (in dollars per share)	2.03
Impact of anti-dilution clauses (in dollars per share)	1.50
Outstanding at end of period (in dollars per share)	1.82	$ 5.24
Exercisable at end of period (in dollars per share)	$ 1.82
Equity and Liability Warrants, Additional Disclosures [Abstract]
Outstanding, weighted average remaining contractual life	3 years 7 months 6 days	2 years 10 months 24 days
Issued	4 years 6 months
Impact of anti-dilution clauses	1 year 3 months 18 days
Exercisable, weighted average remaining contractual life	3 years 7 months 6 days

EQUITY, SHARE-BASED COMPENSAT39

EQUITY, SHARE-BASED COMPENSATION AND WARRANTS, Text (Details) $ / shares in Units, $ in Thousands	1 Months Ended		9 Months Ended
	Sep. 30, 2016$ / sharesshares	Feb. 29, 2016USD ($)$ / sharesshares	Sep. 30, 2016USD ($)$ / sharesshares	Sep. 30, 2015USD ($)	Jun. 30, 2016$ / shares	Jan. 31, 2016USD ($)$ / sharesshares	Dec. 31, 2015shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from issuance of preferred stock and warrants, net of issuance costs		$ 2,600	$ 2,554	$ 0
Warrants [Member] | Expiration January, 2021 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price per warrant (in dollars per share) | $ / shares	$ 1.60		$ 1.60		$ 1.85	$ 5.25
Warrants [Member] | Expiration August, 2021 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants to purchase shares of common stock (in shares) | shares		2,660,000
Exercise price per warrant (in dollars per share) | $ / shares		$ 2
Proceeds allocated to derivative warrant liability		$ 2,500
Warrant exercise price (in dollars per share) | $ / shares		$ 5.24
Reduction in warrants exercise price (in dollars per share) | $ / shares		$ 1.50
Warrants underlying exercisable (in shares) | shares		426,489
Increase in warrants underlying exercisable (in shares) | shares		1,489,868
Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fixed price per share held in escrow by supplier (in dollars per share) | $ / shares		$ 2.80
Series F Preferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Preferred stock authorized for issuance (in shares) | shares	20,000,000	3,000	20,000,000				20,000,000
Preferred shares converted into common stock (in shares) | shares		2,000,000
Preferred stock conversion ratio to common stock		666.66666
Amount per share of preferred stock entitled to receive dividend (in dollars per share) | $ / shares		$ 0.01
Proceeds allocated to preferred stock		$ 500
Fair value of common stock issued		2,700
Series F Preferred Stock [Member] | Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Underwriters cash fee		200
Proceeds from issuance of preferred stock and warrants, net of issuance costs		2,600
Offering expenses		400
Gross proceeds		$ 3,000
Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock to issued to directors (in shares) | shares	174,825
Fair value of common stock granted to director (in dollars per share) | $ / shares	$ 1.46
Directors [Member] | Warrants [Member] | Expiration January, 2021 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants to purchase shares of common stock (in shares) | shares						25,000
Exercise price per warrant (in dollars per share) | $ / shares						$ 5.25
Directors [Member] | Note Payable [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Due to related parties						$ 300
Directors [Member] | Note Payable [Member] | Expiration January, 2021 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Due to related parties						$ 300

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details) - USD ($)	Mar. 24, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015	Feb. 06, 2009	Aug. 28, 2008
Loss Contingencies [Line Items]
Amount of second installment on purchase agreement being withheld		$ 4,387,000				$ 4,387,000		$ 4,789,000
Gain recognized from contingencies		0			$ 0	1,598,000	$ 0
Amount of escrow liability in accrued expenses		$ 0				0		1,921,000
Irgovel [Member] | Minimum [Member]
Irgovel - Events of Default [Abstract]
EBITDA triggering default status						$ 4,000,000
Sellers [Member]
Loss Contingencies [Line Items]
Amount of second installment on purchase agreement being withheld									$ 1,000,000
Amount held in escrow								$ 1,900,000	$ 2,000,000
Amount of escrow released	$ 1,900,000
Repayment of term note	1,000,000
Fine amount per day established by court for violating order	$ 10,000		$ 0
Gain recognized from contingencies				$ 1,600,000
Amount of escrow liability in accrued expenses				1,900,000
Pre-acquisition contingencies				$ 300,000
Pending Litigation [Member] | Former Irgovel Stockholder David Resyng [Member]
Loss Contingencies [Line Items]
Damages sought by plaintiff										$ 3,000,000

SEGMENT INFORMATION (Details)

SEGMENT INFORMATION (Details) - USD ($) $ in Thousands	3 Months Ended			9 Months Ended
	Sep. 30, 2016	Jun. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Segment information identified and reconciliations of segment information to total consolidated information [Abstract]
Revenues	$ 8,824		$ 8,917	$ 29,420	$ 29,982
Cost of goods sold	6,918		6,860	23,293	24,634
Gross profit	1,906		2,057	6,127	5,348
Depreciation and amortization (in selling, general and administrative)	(309)		(426)	(965)	(1,360)
Other operating expense	(3,737)		(2,977)	(14,478)	(9,817)
Loss from operations	(2,140)		(1,346)	(9,316)	(5,829)
Net income (loss) attributable to RiceBran Technologies shareholders	(1,080)		(524)	(7,388)	(7,052)
Interest expense	746		761	2,578	2,434
Depreciation (in costs of goods sold)	462		426	1,291	1,836
Purchases of property	252		416	460	991
Segment information for selected balance sheet accounts [Abstract]
Inventories	3,875			3,875		$ 3,857
Property, net	19,347			19,347		18,328
Goodwill	790			790		3,258
Intangible assets, net	476			476		1,225
Total assets	31,226			31,226		33,635
Goodwill impairment charge	0		0	3,024	0
USA [Member]
Segment information for selected balance sheet accounts [Abstract]
Goodwill	790			790		790
Goodwill impairment charge				0
Brazil [Member]
Segment information for selected balance sheet accounts [Abstract]
Goodwill	0			0		2,468
Goodwill impairment charge	0	$ 3,024		3,024
Corporate [Member]
Segment information identified and reconciliations of segment information to total consolidated information [Abstract]
Revenues	0		0	0	0
Cost of goods sold	0		0	0	0
Gross profit	0		0	0	0
Depreciation and amortization (in selling, general and administrative)	(23)		(22)	(69)	(56)
Other operating expense	(1,784)		(1,067)	(5,445)	(3,687)
Loss from operations	(1,807)		(1,089)	(5,514)	(3,743)
Net income (loss) attributable to RiceBran Technologies shareholders	(861)		(777)	(4,955)	(5,260)
Interest expense	353		348	1,486	999
Depreciation (in costs of goods sold)	0		0	0	0
Purchases of property	0		0	0	0
Segment information for selected balance sheet accounts [Abstract]
Inventories	0			0		0
Property, net	422			422		418
Goodwill	0			0		0
Intangible assets, net	0			0		0
Total assets	1,869			1,869		3,497
Operating Segments [Member] | USA [Member]
Segment information identified and reconciliations of segment information to total consolidated information [Abstract]
Revenues	8,261		5,036	24,793	16,988
Cost of goods sold	5,764		3,719	17,190	11,770
Gross profit	2,497		1,317	7,603	5,218
Depreciation and amortization (in selling, general and administrative)	(270)		(393)	(854)	(1,181)
Other operating expense	(1,460)		(1,141)	(4,160)	(3,340)
Loss from operations	767		(217)	2,589	697
Net income (loss) attributable to RiceBran Technologies shareholders	767		(217)	2,589	697
Interest expense	0		0	0	0
Depreciation (in costs of goods sold)	216		206	619	643
Purchases of property	166		72	231	423
Segment information for selected balance sheet accounts [Abstract]
Inventories	3,524			3,524		3,302
Property, net	7,787			7,787		8,408
Goodwill	790			790		790
Intangible assets, net	476			476		1,225
Total assets	16,172			16,172		15,260
Operating Segments [Member] | Brazil [Member]
Segment information identified and reconciliations of segment information to total consolidated information [Abstract]
Revenues	563		3,881	4,627	12,994
Cost of goods sold	1,154		3,141	6,103	12,864
Gross profit	(591)		740	(1,476)	130
Depreciation and amortization (in selling, general and administrative)	(16)		(11)	(42)	(123)
Other operating expense	(493)		(769)	(4,873)	(2,790)
Loss from operations	(1,100)		(40)	(6,391)	(2,783)
Net income (loss) attributable to RiceBran Technologies shareholders	(986)		470	(5,022)	(2,489)
Interest expense	393		413	1,092	1,435
Depreciation (in costs of goods sold)	246		220	672	1,193
Purchases of property	86		$ 344	229	$ 568
Segment information for selected balance sheet accounts [Abstract]
Inventories	351			351		555
Property, net	11,138			11,138		9,502
Goodwill	0			0		2,468
Intangible assets, net	0			0		0
Total assets	$ 13,185			$ 13,185		$ 14,878

SEGMENT INFORMATION, Revenue by

SEGMENT INFORMATION, Revenue by Geographic Area (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	$ 8,824	$ 8,917	$ 29,420	$ 29,982
Reportable Geographic Segment [Member] | USA [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	7,740	6,267	23,113	18,090
Reportable Geographic Segment [Member] | Brazil [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	289	255	3,264	6,157
Reportable Geographic Segment [Member] | Other International [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	$ 795	$ 2,395	$ 3,043	$ 5,735

FAIR VALUE MEASUREMENTS (Detail

FAIR VALUE MEASUREMENTS (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Fair values by input hierarchy of items measured at fair value on a recurring basis [Abstract]
Total liabilities at fair value	$ 10,200
Brazil [Member]
Fair values by input hierarchy of items measured at fair value on a recurring basis [Abstract]
Total liabilities at fair value	6,800
Derivative Warrant Liability [Member] | Recurring [Member]
Fair values by input hierarchy of items measured at fair value on a recurring basis [Abstract]
Total liabilities at fair value	$ 2,838	$ 678
Derivative Warrant Liability [Member] | Recurring [Member] | Minimum [Member]
Additional assumptions used to calculate fair value [Abstract]
Risk-free interest rate	0.60%	0.90%
Expected volatility	69.00%	71.00%
Derivative Warrant Liability [Member] | Recurring [Member] | Maximum [Member]
Additional assumptions used to calculate fair value [Abstract]
Risk-free interest rate	0.90%	1.20%
Expected volatility	85.00%	89.00%
Derivative Warrant Liability [Member] | Recurring [Member] | Weighted Average [Member]
Additional assumptions used to calculate fair value [Abstract]
Risk-free interest rate	0.80%	1.10%
Expected volatility	81.00%	78.00%
Derivative Warrant Liability [Member] | Level 1 [Member] | Recurring [Member]
Fair values by input hierarchy of items measured at fair value on a recurring basis [Abstract]
Total liabilities at fair value	$ 0	$ 0
Derivative Warrant Liability [Member] | Level 2 [Member] | Recurring [Member]
Fair values by input hierarchy of items measured at fair value on a recurring basis [Abstract]
Total liabilities at fair value	0	0
Derivative Warrant Liability [Member] | Level 3 [Member] | Recurring [Member]
Fair values by input hierarchy of items measured at fair value on a recurring basis [Abstract]
Total liabilities at fair value	$ 2,838	$ 678

FAIR VALUE MEASUREMENTS, Unobse

FAIR VALUE MEASUREMENTS, Unobservable Input Reconciliation (Details) - Recurring [Member] - Derivative Warrant Liability [Member] - USD ($) $ in Thousands		9 Months Ended
		Sep. 30, 2016	Sep. 30, 2015
Changes in level 3 items measured at fair value on a recurring basis [Roll Forward]
Fair Value as of Beginning of Period		$ (678)	$ (955)
Total Realized and Unrealized Gains (Losses)	[1]	314	1,211
Issuance of New Instruments		(2,474)	(724)
Fair Value, at End of Period		$ (2,838)	$ (468)
[1]	Included in change in fair value of derivative warrant liabilities in our unaudited condensed consolidated statements of operations.

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details) - USD ($)	Jul. 05, 2016	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Jan. 31, 2016
Related Party Transaction [Line Items]
Interest paid				$ 1,319,000	$ 1,306,000
LF-RB Group [Member]
Related Party Transaction [Line Items]
Ownership interest percentage	9.00%
Legal fees and other expenses paid in cash	$ 50,000
Legal fees and other expense paid in shares (in shares)	100,000
Baruch Halpern [Member] | Note Payable [Member]
Related Party Transaction [Line Items]
Due to related parties						$ 300,000
Stated annual interest rate						11.75%
Baruch Halpern [Member] | Note Payable [Member] | Expiration January, 2021 [Member]
Related Party Transaction [Line Items]
Due to related parties						$ 300,000
Baruch Halpern [Member] | Subordinated Notes [Member]
Related Party Transaction [Line Items]
Due to related parties		$ 2,600,000		2,600,000
Additioanl amount, due to related party		137,500
Interest paid		100,000	$ 100,000	200,000	200,000
Baruch Halpern [Member] | Warrants [Member] | Expiration January, 2021 [Member]
Related Party Transaction [Line Items]
Number of warrants issued to acquire shares of common stock (in shares)						25,000
Exercise price of warrants (in dollars per share)						$ 5.25
W. John Short [Member] | Subordinated Notes [Member]
Related Party Transaction [Line Items]
Due to related parties		50,000		50,000
Interest paid		$ 2,000	$ 2,000	$ 5,000	$ 5,000

FAILURE TO COMPLY WITH NASDAQ46

FAILURE TO COMPLY WITH NASDAQ LISTING REQUIREMENTS (Details) - USD ($)	Aug. 18, 2016	Sep. 30, 2016	Jun. 30, 2016	Dec. 31, 2015
FAILURE TO COMPLY WITH NASDAQ LISTING REQUIREMENTS [Abstract]
Nasdaq minimum stockholders' equity listing requirement	$ 2,500,000
Stockholders' equity (deficit)		$ (1,190,000)	$ (36,000,000)	$ 7,268,000
Nasdaq grant of extension period to regain compliance	180 days

SEVERANCE ACTIVITIES (Details)

SEVERANCE ACTIVITIES (Details)	Sep. 30, 2016USD ($)
SEVERANCE ACTIVITIES [Abstract]
Accrued estimated severance payments	$ 700,000